Innovation at Penn
Browse Penn-owned technologies available for licensing.
Search Results - william degrado
Small molecule inhibitors of Integrin α2β1
Problem: There is a need for new therapeutics that prevent cardiovascular diseases with minimal effects on normal blood clotting. Integrin α2β1 is a good therapeutic target since it can lead to cardiovascular diseases including stroke or myocardial infarction when overexpressed, but does not severely impair normal bleeding when under-expressed....
Therapeutics & Vaccines
© 2020. All Rights Reserved. Powered by